Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Moodys
Johnson and Johnson
McKesson
Citi
Baxter
Cipla
Boehringer Ingelheim

Generated: September 23, 2018

DrugPatentWatch Database Preview

Metuchen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for METUCHEN PHARMS, and what generic alternatives to METUCHEN PHARMS drugs are available?

METUCHEN PHARMS has one approved drug.

There are two US patents protecting METUCHEN PHARMS drugs.

Summary for Metuchen Pharms
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Metuchen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 7,501,409 ➤ Sign Up Y ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes 6,656,935 ➤ Sign Up Y Y ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes 7,501,409 ➤ Sign Up Y ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No 6,656,935 ➤ Sign Up Y Y ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 7,501,409 ➤ Sign Up Y ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No 6,656,935 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for METUCHEN PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-04-27

Supplementary Protection Certificates for Metuchen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00040 Denmark ➤ Sign Up
90047-7 Sweden ➤ Sign Up PRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621
13/041 Ireland ➤ Sign Up PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613
6 Finland ➤ Sign Up
249 Luxembourg ➤ Sign Up PRODUCT NAME: AVANAFIL
2013000096 Germany ➤ Sign Up PRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621
C0050 France ➤ Sign Up PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
Deloitte
McKinsey
US Department of Justice
Medtronic
Moodys
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.